The International Commission on the Clinical Use of Human Germline Genome Editing has been convened by the U.S. National Academy of Medicine (NAM), the U.S. National Academy of Sciences (NAS), and the Royal Society of the U.K., with the participation of science and medical academies around the world, to develop a framework for scientists, clinicians, and regulatory authorities to consider when assessing potential clinical applications of human germline genome editing. The framework will identify a number of scientific, medical, and ethical requirements that should be considered, and could inform the development of a potential pathway from research to clinical use — if society concludes that heritable human genome editing applications are acceptable.
- Sonia Abdelhak (Institut Pasteur de Tunis, Tunisia)
- Fabiana Arzuaga (Ministry of Science, Technology and Productive Innovation, Argentina)
- Muntaser Ibrahim (University of Khartoum, Sudan)
The webcast of the event is available here: